MagicMed files with the USPTO with respect to its "broad portfolio of novel psilocybin molecular derivatives, the Psybrary™".
Psychedelic drug R&D is ramping up rapidly. The number of past and current clinical studies on these substances will surprise you.
Mydecine's new Scientific Advisor holds over 150 U.S. and international patents and will oversee Mydecine's mycology lab.
Mydecine Innovations Group has added one of the world's pre-eminent biotech scientists to its Scientific Advisory Board.
The Psychedelics Revolution. One part changing social attitudes. One part medical necessity. One part hard economics.